Showing results (1-10 of 67) with videos related to
Sort By:
Pageof 7
Digestive Diseases (Basel, Switzerland)|November 20, 2013
Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrinTaina SipponenDuodecim; Laaketieteellinen Aikakauskirja|February 11, 2012
[Faecal calprotectin in inflammatory bowel disease]Taina Sipponen, Kaija-Leena KolhoScandinavian Journal of Gastroenterology|April 10, 2010
Faecal calprotectin in children with clinically quiescent inflammatory bowel diseaseTaina Sipponen, Kaija-Leena KolhoScandinavian Journal of Gastroenterology|December 20, 2014
Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel diseaseTaina Sipponen, Kaija-Leena KolhoDuodecim; Laaketieteellinen Aikakauskirja|March 26, 2013
[Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases]Taina Sipponen, Kaija-leena KolhoScandinavian Journal of Gastroenterology|March 7, 2014
The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel diseaseKaija-Leena Kolho, Taina SipponenScandinavian Journal of Gastroenterology|March 28, 2019
Fragmented management of long-term parenteral support for adult intestinal failure in FinlandAnne Pohju, Mikko P Pakarinen, Taina SipponenWorld Journal of Gastroenterology|January 5, 2012
Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levelsAnssi Hämäläinen, Taina Sipponen, Kaija-Leena KolhoDuodecim; Laaketieteellinen Aikakauskirja|August 28, 2014
[New treatment options for inflammatory bowel diseases]Taina Sipponen, Martti Färkkilä, Kaija-Leena KolhoScandinavian Journal of Gastroenterology|November 15, 2012
Serum infliximab concentrations in pediatric inflammatory bowel diseaseAnssi Hämäläinen, Taina Sipponen, Kaija-Leena KolhoPageof 7